Jiangsu Alphamab Biopharmaceuticals Co., Ltd

3 in Phase 3

Quick facts

Phase 3 pipeline

Eribulin mesylate injection · Oncology
Eribulin mesylate is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.
JSKN003 · Oncology
JSKN003 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
KN046 · Oncology
KN046 is a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells to enhance anti-tumor immune responses.

Phase 2 pipeline

Concurrent chemotherapy and KN026 · Oncology
KN026 is a monoclonal antibody targeting PD-L1.
JSKN016 injection · Oncology
JSKN016 injection is a monoclonal antibody targeting PD-1.
KN026 monotherapy

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Jiangsu Alphamab Biopharmaceuticals Co., Ltd

What is Jiangsu Alphamab Biopharmaceuticals Co., Ltd's pipeline?

Jiangsu Alphamab Biopharmaceuticals Co., Ltd has 3 drugs in Phase 3, 3 in Phase 2, 5 in Phase 1. Late-stage candidates include Eribulin mesylate injection, JSKN003, KN046.

Sector hub: All tracked pharma companies